Staff

BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S....

First Ever FDA Authorized Over-the-Counter At-Home Rapid Test Kit For Coronavirus Backed by Biden Administration, as Global WholeHealth Partners Corp. Pioneers The Only Biodegradable Plant Based Plastic for Medical Devices

error: Content is protected !!